ABOUT US

Aerami Therapeutics is developing novel inhaled therapies for the treatment of chronic diseases.

Our platform combines a smart inhaler with proprietary soft mist biologic formulations for optimal and precise delivery of therapies through the lungs. This platform is designed to overcome limitations of injectable and other inhaled formulation technologies for managing chronic diseases, and ultimately improve treatment efficacy and patient experience.

OUR TECHNOLOGY
| The Next Generation Smart Inhaler

  • Vibrating mesh technology generates a soft mist that allows for a drug deposition 2-4x higher than conventional inhalers1
  • Breath-activated for precise dosing; visual indicator verifies correct breathing
  • Silent and discreet
  • Easily loaded and cleaned
  • Low cost; Durable (1+ year life)
  • Bluetooth-enabled with possible integration with connected devices and real time treatment data collection
  • Potential for patient engagement to improve compliance

Soft mist inhaled

THERAPIES

OUR PIPELINE

Aerami Therapeutics is developing a diverse pipeline of soft mist inhaled therapies with initial focus on rare and severe diseases in the endocrinology, respiratory and cardiovascular space, where our platform and expertise present a unique opportunity to achieve better treatment efficiency.

501

HUMAN INSULIN

601

SHORT ACTING GLUCAGON
LIKE PEPTIDE (GLP-1) ANALOG

701

INHALED PARATHYROID
HORMONE (PTH) FOR
HYPOPARATHYROIDISM

801

INHALED HUMAN GROWTH
HORMONE (HGH) FOR GROWTH
HORMONE DISORDER

MANAGEMENT TEAM

Our management team brings together formulation,
device development, clinical and commercial expertise.

ANNE WHITAKER

Chief Executive Officer

MICHAEL J. KASETA

Chief Financial Officer

MELISSA RHODES, PhD, DABT

Chief Development Officer

MEI-CHANG KUO, PhD

Senior Vice President
Pharmaceutics

TRUC LE

Chief Technical Operations
& Manufacturing

BOARD OF DIRECTORS

Anne Whitaker, Chief Executive Officer and Director

John Patton, PhD, Director and Founder

Steve Thornton, Director, Chair of Compensation Committee

Adam Stern, Director

Benjamin Wolin, Interim Chairman, Chair of Nomination and Governance Committee

Matt Jennings, Director

Kenneth B. Lee, Jr. Director, Chair of Audit Committee